Clinical Trials Logo

Triple Negative Breast Cancer clinical trials

View clinical trials related to Triple Negative Breast Cancer.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04916002 Suspended - Clinical trials for Non-Small Cell Lung Cancer

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Start date: November 30, 2021
Phase: Phase 2
Study type: Interventional

The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: - How many participants' cancers respond to vidutolimod together with cemiplimab? - Is vidutolimod together with cemiplimab safe and well-tolerated? - How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.

NCT ID: NCT04803084 Suspended - Breast Cancer Clinical Trials

Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

Start date: August 9, 2021
Phase:
Study type: Observational

This study is looking at how an imaging test could help doctors understand if a patient with early breast cancer will respond to drugs that use the patient's immune system to fight cancer.

NCT ID: NCT04095689 Suspended - Clinical trials for Triple Negative Breast Cancer

Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer

INTEGRAL
Start date: March 17, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory, triple negative breast cancer (TNBC).

NCT ID: NCT03777579 Suspended - Clinical trials for Triple Negative Breast Cancer

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

This multicenter, randomized, double-blind study will evaluate the efficacy, safety of JS001 administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel as first-line therapy in participants with primarily diagnosed stage IV and recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

NCT ID: NCT03002103 Suspended - Clinical trials for Triple-Negative Breast Cancer

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Start date: November 23, 2016
Phase: Phase 3
Study type: Interventional

This is a prospective, multicenter, open-label, randomized, and controlled trial to test the superiority of EndoTAG®-1 in combination with paclitaxel and gemcitabine versus paclitaxel in combination with gemcitabine. An independent data safety monitoring board (DSMB) will be established to decide on the recommended dose (RD) of EndoTAG®-1, paclitaxel and gemcitabine to be used throughout the trial and to monitor the patients' safety and treatment efficacy data